Ligand Pharmaceuticals Incorporated is a biopharmaceutical company focused on developing and licensing biopharmaceutical assets globally. They have a diverse portfolio of commercial programs, including treatments for multiple myeloma, acute lymphoblastic leukemia, and rare kidney diseases. Ligand Pharmaceuticals also develops technologies that enhance the solubility and stability of drugs, notably their Captisol platform.

Due to the absence of transcript information, a direct graphical representation of spoken content is not possible. However, we can leverage the financial data to create visualizations that showcase key financial trends and performance indicators.

Ligand's Captisol technology is used in over 80 FDA-approved products, including Veklury (remdesivir), a treatment for COVID-19! This highlights the impact and importance of Ligand's contributions to the pharmaceutical industry.